Physician profile
Stephen Ksiazek
NPI 1851346738
$2,887.25
in general payments reported to CMS, 2019-2025
23 companies · $303 in 2025
The $303 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $175 · 2021: $784 · 2022: $493 · 2023: $1,008 · 2024: $125 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $516.60 | 2020-2024 | Brilinta, Lokelma, Farxiga |
| Janssen Pharmaceuticals, INC | $357.01 | 2021-2023 | Xarelto |
| Medtronic, INC. | $315.49 | 2021-2025 | Corevalve Evolut R, Symplicity G3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.08 | 2021-2023 | Jardiance, Tradjenta, Glyxambi |
| Esperion Therapeutics, INC. | $198.05 | 2021 | |
| Shockwave Medical, INC | $170.06 | 2025 | |
| Mannkind Corporation | $135.29 | 2022-2023 | Afrezza |
| Boston Scientific Corporation | $120.98 | 2020 | |
| Edwards Lifesciences Corporation | $108.27 | 2021 | |
| Pfizer INC. | $91.27 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $79.03 | 2022-2023 | Recorlev |
| Kiniksa Pharmaceuticals, LTD. | $77.00 | 2022-2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $76.40 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $70.69 | 2023 | Eliquis |
| Merck Sharp & Dohme LLC | $69.16 | 2022-2023 | Verquvo, Steglatro |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $59.36 | 2021 | |
| Novartis Pharmaceuticals Corporation | $57.39 | 2022-2023 | |
| Novo Nordisk INC | $50.16 | 2023 | Ozempic, Rybelsus |
| Medtronic Vascular, INC. | $41.71 | 2020 | |
| Philips North America LLC | $24.67 | 2022 | |
| Alexion Pharmaceuticals, INC. | $24.58 | 2023 | |
| Lilly USA, LLC | $23.29 | 2022 | |
| Insulet Corporation | $22.71 | 2023 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ksiazek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.